Munich, October 6th 2010 – Hepa Wash GmbH was invited to showcase its patented liver support device at the MedTech Summit 2010 in Lausanne, Switzerland. In total, 24 companies from nine different countries in Europe and Israel out of 250 potential candidates were selected by a jury of highly regarded European professionals to attend at the event. “These companies represent some of the most exciting medtech technologies in Europe and Israel at the moment,” said Bill Muirhead, President of the 2010 Medtech Summit and Chairman and co-founder of biotech company Ayanda Biosystems.
“We are very proud that the jury recognizes our liver support device as one of the most promising technologies which can potentially deliver significant patient benefits in a cost efficient manner to impact global healthcare,” said Dr. Bernhard Kreymann, CEO of Hepa Wash.
For Hepa Wash the MedTech Summit is the prelude to its next financing round. In the last five years the company raised 5,5 million euros capital money in two successful financing rounds about two million euros in grants. The ongoing pilot study in man and the CE certification of the liver support device are financially covered. The current financing is sought for performing the clinical multicenter studies and the market entry in 2011. The current investors will participate in this financing round. The current financing round has a volume of ten million euros.
About Hepa Wash GmbH
Hepa Wash GmbH, which is located in the “Munich Technology Center” (MTZ), works since its foundation in 2005 on a new liver support therapy, to reduce the high mortality of critically ill patients with liver failure. Recent studies revealed that existing therapies can hardly achieve any positive effects on survival of liver patients. However, the Hepa Wash procedure has a significantly increased detoxication capacity and is therefore expected to improve the survival rate of affected patients for at least 30 percent. Two in-vitro- and preclinical studies already showed the imposing beneficial effects of the procedure. The clinical study at II. Medical Clinic in Hospital rechts der Isar started in September 2010. First results are expected in the end of the year. For this study a TUEV approved prototype of the device is used. In parallel to the pilot study the company finishes the device for the CE certification.
More Information Design of the clinically studies. Description of Hepa Wash technology.
Contact Daniela Becker, Press Officer
Hepa Wash GmbH Agnes-Pockels-Bogen 1 • 80992 Munich • Germany Phone: +49 (89) 4111842-24 • Fax: +49 (89) 4111842-09 Email: Daniela.Becker@hepawash.com • Web: www.hepawash.com CEO: PD Dr. Bernhard Kreymann • Chairman of the supervisory board: Harald Pinger Commercial register of the local court (Amtsgericht) München HRB 150 905 • VAT ID: DE235056961
